The effects of
Acute lung injury
COVID-19
N-acetyl cysteine
NAC
Respiratory distress syndrome
Journal
Advances in integrative medicine
ISSN: 2212-9588
Titre abrégé: Adv Integr Med
Pays: Netherlands
ID NLM: 101654496
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
pubmed:
25
8
2020
medline:
25
8
2020
entrez:
25
8
2020
Statut:
ppublish
Résumé
Current evidence suggests that N-Acetyl Cysteine (NAC) administration may help improve outcomes in people with acute respiratory distress syndrome and acute lung injury - conditions that closely resemble the signs and symptoms of COVID-19. Few mild and transient adverse events were reported in published randomised-controlled trials, indicating that NAC may be reasonably safe. These findings suggest that NAC may complement the management of COVID-19 infection, particularly when administered intravenously within an intensive care unit (ICU) environment.
Identifiants
pubmed: 32837898
doi: 10.1016/j.aimed.2020.07.006
pii: S2212-9588(20)30139-7
pmc: PMC7398034
doi:
Types de publication
Journal Article
Langues
eng
Pagination
232-239Informations de copyright
© 2020 Elsevier Ltd. All rights reserved.
Références
Respir Med. 2009 Mar;103(3):434-41
pubmed: 18993042
J Crit Care. 1997 Dec;12(4):177-82
pubmed: 9459113
Chest. 1997 Jul;112(1):164-72
pubmed: 9228372
Chest. 1996 Jan;109(1):163-6
pubmed: 8549180
JAMA. 2018 Mar 13;319(10):993-1001
pubmed: 29486489
Crit Care Med. 1992 Jul;20(7):918-23
pubmed: 1617983
Medicine (Baltimore). 2018 Nov;97(45):e13087
pubmed: 30407312
Med Gas Res. 2018 Apr 18;8(1):19-23
pubmed: 29770192
Am J Crit Care. 2015 Sep;24(5):440-5
pubmed: 26330437
Hum Exp Toxicol. 2007 Sep;26(9):697-703
pubmed: 17984140
Chest. 1994 Jan;105(1):190-4
pubmed: 8275731
Ann Intern Med. 2010 May 18;152(10):687-8
pubmed: 20479037
Shock. 2000 Jan;13(1):14-8
pubmed: 10638663